- Home
- APLM vs CSCI Comparison
APLM vs CSCI Comparison
Compare APLM & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- CSCI
- Stock Information
- Founded
- APLM 2016
- CSCI 1990
- Country
- APLM United States
- CSCI Canada
- Employees
- APLM N/A
- CSCI N/A
- Industry
- APLM Blank Checks
- CSCI
- Sector
- APLM Finance
- CSCI
- Exchange
- APLM Nasdaq
- CSCI NYSE
- Market Cap
- APLM 15.6M
- CSCI 11.1M
- IPO Year
- APLM N/A
- CSCI 1996
- Fundamental
- Price
- APLM $9.75
- CSCI $2.50
- Analyst Decision
- APLM Strong Buy
- CSCI
- Analyst Count
- APLM 2
- CSCI 0
- Target Price
- APLM $425.00
- CSCI N/A
- AVG Volume (30 Days)
- APLM 102.2K
- CSCI 4.0K
- Earning Date
- APLM 02-15-2025
- CSCI 11-12-2024
- Dividend Yield
- APLM N/A
- CSCI N/A
- EPS Growth
- APLM N/A
- CSCI N/A
- EPS
- APLM N/A
- CSCI N/A
- Revenue
- APLM $2,101,000.00
- CSCI $4,834,000.00
- Revenue This Year
- APLM N/A
- CSCI N/A
- Revenue Next Year
- APLM N/A
- CSCI N/A
- P/E Ratio
- APLM N/A
- CSCI N/A
- Revenue Growth
- APLM 70.54
- CSCI N/A
- 52 Week Low
- APLM $6.50
- CSCI $2.50
- 52 Week High
- APLM $105.00
- CSCI $11.10
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- CSCI N/A
- Support Level
- APLM $7.23
- CSCI N/A
- Resistance Level
- APLM $8.88
- CSCI N/A
- Average True Range (ATR)
- APLM 1.37
- CSCI 0.00
- MACD
- APLM 0.21
- CSCI 0.00
- Stochastic Oscillator
- APLM 57.91
- CSCI 0.00
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.